Cadila gets USFDA approval for Chlorthalidone tablets
Zydus Cadila today informed the bourses that it has received final approval from the USFDA to market Chlorthalidone tablets, 25 mg and 50 mg.
Chlorthalidone tablets are used to treat hypertension. These are also used to reduce extra salt and water in the body caused by conditions such as heart failure, liver disease, and kidney disease.
The group has 266 approvals and has so far filed over 350 ANDAs since the commencement of the filing process.
Cadila's FY18 revenue mix comprised US formulations (50 per cent), India formulations (29 per cent), EMB formulations (6 per cent), animal health (4 per cent), wellness (4 per cent), APIs (3 per cent), alliances (2 per cent) and Europe dormulations (2 per cent).
During the recently concluded quarter Q3FY19, the company witnessed 10 per cent yoy increase in its revenue. However, the bottomline has declined by 6 per cent on a yoy basis.
On Monday, the stock of Cadila Healthcare opened at Rs. 280 and made an intra-day low of Rs 272.30 on the BSE. At 14:36 hours, the stock was trading nearly at Rs. 274.60 on the BSE. The stock had hit its 52-week high of Rs 432.40 on September 10, 2018 and its 52-week low of Rs. 272.30 on May 13, 2019 on the BSE.